High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: Complete remission at transplantation is the major determinant of outcome - Lymphoma working party of the European group for blood and marrow transplantation

被引:108
|
作者
Kyriakou, Charalampia
Canals, Carmen
Goldstone, Anthony
Caballero, Dolores
Metzner, Bernd
Kobbe, Guido
Kolb, Hans-Jochem
Kienast, Joachim
Reimer, Peter
Finke, Jurgen
Oberg, Gunnar
Hunter, Ann
Theorin, Niklas
Sureda, Anna
Schmitz, Norbert
机构
[1] UCL, Northwood HA6 3NG, Middx, England
[2] European Bone Marrow Transplantat Grp, London, England
[3] Leicester Royal Infirm, Leicester, Leics, England
[4] Hosp Clin Serv Hematol, Salamanca, Spain
[5] Hosp Santa Creu & Sant Pau, E-08025 Barcelona, Spain
[6] Univ Hosp, Dept Med, Uppsala, Sweden
[7] Univ Freiburg, Dept Med Hematol Oncol, D-7800 Freiburg, Germany
[8] Univ Wurzburg, Med Klin, D-8700 Wurzburg, Germany
[9] Univ Munster, Dept Hematol Oncol, Munster, Germany
[10] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany
[11] Univ Dusseldorf, Dusseldorf, Germany
[12] Klin Oldenburg, Hamatol Onkol Abt, Oldenburg, Germany
关键词
D O I
10.1200/JCO.2007.12.6219
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Patients with angioimmunoblastic T-cell lymphoma (AITL) have poor prognoses with current conventional chemotherapy. The aim of this study was to evaluate the effect of high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) on patients with AITL. Patients and Methods We report a retrospective, multicenter study of 146 patients with AITL who received ASCT. The source of the stem cells was peripheral blood in 143 patients. The conditioning regimen varied, and 74% of the patients received carmustine and 1,3-bis(2-chloroethyl)-1-nitrosourea; etoposide; ara-C; and melphalan chemotherapy. Results After a median follow-up of 31 months (range, 3 to 174 months), 95 patients (65%) remained alive, and 51 patients (35%) died. Forty-two patients died as a result of disease progression, and nine died as a result of regimen-related toxicity. The cumulative incidence of nonrelapse mortality was 5% and 7% at 12 and 24 months, respectively. The actuarial overall survival (OS) was 67% at 24 months and 59% at 48 months. The cumulative incidence of relapse was estimated at 40% and 51% at 24 and 48 months, respectively. Disease status at transplantation was the major factor that impacted outcome. Patients who received a transplant during first complete remission (CR) had significantly superior progression-free survival and OS. The estimated PFS rates for patients who received their transplants in CR were 70% and 56% at 24 and 48 months, respectively; 42% and 30% for patients with chemotherapy-sensitive disease at those time points, respectively; and 23% at both time points for patients with chemotherapy- refractory disease. Conclusion This study shows that HDT and ASCT offers the possibility of long-term disease-free survival to patients with AITL. Early transplantation is necessary to achieve optimal results.
引用
收藏
页码:218 / 224
页数:7
相关论文
共 50 条
  • [21] THE ROLE OF HIGH-DOSE THERAPY AND ALLOGRAFTING STEM-CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA
    Guillermo, A. Lopez
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 33 - 33
  • [22] PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION AFTER HIGH-DOSE THERAPY IN PATIENTS WITH MALIGNANT-LYMPHOMA - A RETROSPECTIVE COMPARISON WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    AGER, S
    SCOTT, MA
    MAHENDRA, P
    RICHARDS, EM
    JESTICE, HK
    BORAKS, P
    BAGLIN, TP
    MARCUS, RE
    [J]. BONE MARROW TRANSPLANTATION, 1995, 16 (01) : 79 - 83
  • [23] High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma
    Gabarre, J
    Azar, N
    Autran, B
    Katlama, C
    Leblond, V
    [J]. LANCET, 2000, 355 (9209): : 1071 - 1072
  • [24] High-dose therapy with autologous stem-cell transplantation in aggressive non-Hodgkin's lymphoma
    Verdonck, LF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 3003 - 3003
  • [25] Autologous stem-cell transplantation in patients with primary testicular lymphoma - a study of the Lymphoma Working Party of the EBMT
    Symeonidis, A.
    Canals, C.
    Taghibour, G.
    Martinelli, G.
    Blaise, D.
    Harousseau, J. L.
    Colombat, P.
    Rambaldi, A.
    Goldstone, A.
    Sureda, A.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 39 : S147 - S147
  • [26] Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
    Kyriakou, Charalampia
    Canals, Carmen
    Finke, Juergen
    Kobbe, Guido
    Harousseau, Jean-Luc
    Kolb, Hans-Jochem
    Novitzky, Nicolas
    Goldstone, Anthony H.
    Sureda, Anna
    Schmitz, Norbert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : 3951 - 3958
  • [27] The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma
    Pham, R. N.
    Gooley, T. A.
    Keeney, G. E.
    Press, O. W.
    Pagel, J. M.
    Greisman, H. A.
    Bensinger, W. I.
    Holmberg, L. A.
    Petersdorf, S. H.
    Maloney, D. G.
    Gopal, A. K.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 40 (11) : 1039 - 1044
  • [28] Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation
    Dietrich, Sascha
    Dreger, Peter
    Hermine, Olivier
    Kyriakou, Chara
    Montoto, Silvia
    Robinson, Steve
    Schmitz, Norbert
    Schouten, Harry C.
    Sureda, Anna
    Tanase, Alina
    [J]. BONE MARROW TRANSPLANTATION, 2020, 55 (02) : 317 - 324
  • [29] Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation
    Sascha Dietrich
    Peter Dreger
    Olivier Hermine
    Chara Kyriakou
    Silvia Montoto
    Steve Robinson
    Norbert Schmitz
    Harry C Schouten
    Anna Sureda
    Alina Tanase
    [J]. Bone Marrow Transplantation, 2020, 55 : 317 - 324
  • [30] The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma
    R N Pham
    T A Gooley
    G E Keeney
    O W Press
    J M Pagel
    H A Greisman
    W I Bensinger
    L A Holmberg
    S H Petersdorf
    D G Maloney
    A K Gopal
    [J]. Bone Marrow Transplantation, 2007, 40 : 1039 - 1044